290 related articles for article (PubMed ID: 35605893)
21. Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population.
Asadullah M; Shivashankar R; Shalimar ; Kandasamy D; Kondal D; Rautela G; Peerzada A; Grover B; Amarchand R; Nayak B; Sharma R; Ramakrishnan L; Prabhakaran D; Krishnan A; Tandon N
PLoS One; 2022; 17(2):e0263768. PubMed ID: 35143562
[TBL] [Abstract][Full Text] [Related]
22. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
23. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
Avcu A; Kaya E; Yilmaz Y
Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Sangha K; Chang ST; Cheung R; Deshpande VS
Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
28. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Imajo K; Honda Y; Kobayashi T; Nagai K; Ozaki A; Iwaki M; Kessoku T; Ogawa Y; Takahashi H; Saigusa Y; Yoneda M; Kirikoshi H; Utsunomiya D; Aishima S; Saito S; Nakajima A
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):908-917.e11. PubMed ID: 33340780
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity.
Chen J; Yin M; Talwalkar JA; Oudry J; Glaser KJ; Smyrk TC; Miette V; Sandrin L; Ehman RL
Radiology; 2017 May; 283(2):418-428. PubMed ID: 27861111
[TBL] [Abstract][Full Text] [Related]
31. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
32. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
34. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS.
Xie R; Zhang Y
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1179-1189. PubMed ID: 36964061
[TBL] [Abstract][Full Text] [Related]
35. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
36. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).
Eskridge W; Vierling JM; Gosbee W; Wan GA; Hyunh ML; Chang HE
PLoS One; 2021; 16(11):e0260320. PubMed ID: 34847156
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Dincses E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter.
Mak LY; Chan AC; Wong TC; Dai WC; She WH; Ma KW; Sin SL; Chu KW; Seto WK; Yuen MF; Lo CM; Fung J
BMC Gastroenterol; 2023 Sep; 23(1):307. PubMed ID: 37700227
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
[TBL] [Abstract][Full Text] [Related]
40. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.
Tapper EB; Challies T; Nasser I; Afdhal NH; Lai M
Am J Gastroenterol; 2016 May; 111(5):677-84. PubMed ID: 26977758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
